PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34028522-9	2021	(1) The F-domain, which is connected to helix 12, controls 4-hydroxytamoxifen (4OHT) mediated AF-1 activation associated with the receptor dimerization activity.	hydroxytamoxifen	59-77	interferon gamma receptor 2	Homo sapiens	94-98
33519190-3	2021	Our oligonucleotide microarray revealed that microRNA (miR)-15b is the most significantly downregulated miRNA in MCF-7/4-hydroxytamoxifen (4-OHT) cells treated with Pae.	hydroxytamoxifen	119-137	microRNA 15b	Homo sapiens	45-63
33226686-3	2021	Here we describe and characterize a novel mouse line, Egr1-CreERT2 , which carries a transgene in which the promoter of the immediate early gene Egr1 drives the expression of the CreERT2 recombinase that is only active in the presence of tamoxifen metabolite, 4-hydroxy-tamoxifen (4-OHT).	hydroxytamoxifen	260-279	early growth response 1	Mus musculus	54-58
33226686-3	2021	Here we describe and characterize a novel mouse line, Egr1-CreERT2 , which carries a transgene in which the promoter of the immediate early gene Egr1 drives the expression of the CreERT2 recombinase that is only active in the presence of tamoxifen metabolite, 4-hydroxy-tamoxifen (4-OHT).	hydroxytamoxifen	260-279	mitogen-activated protein kinase 3	Mus musculus	59-66
33226686-3	2021	Here we describe and characterize a novel mouse line, Egr1-CreERT2 , which carries a transgene in which the promoter of the immediate early gene Egr1 drives the expression of the CreERT2 recombinase that is only active in the presence of tamoxifen metabolite, 4-hydroxy-tamoxifen (4-OHT).	hydroxytamoxifen	260-279	early growth response 1	Mus musculus	145-149
33226686-3	2021	Here we describe and characterize a novel mouse line, Egr1-CreERT2 , which carries a transgene in which the promoter of the immediate early gene Egr1 drives the expression of the CreERT2 recombinase that is only active in the presence of tamoxifen metabolite, 4-hydroxy-tamoxifen (4-OHT).	hydroxytamoxifen	260-279	mitogen-activated protein kinase 3	Mus musculus	179-186
33466512-6	2021	The proliferation of MCF-7/Akt cells is partially independent of estradiol (E2) and exhibits an incomplete response to the anti-estrogen agent 4-hydroxytamoxifen, demonstrating the resistance of these cells to hormone therapy.	hydroxytamoxifen	143-161	AKT serine/threonine kinase 1	Homo sapiens	27-30
33064293-0	2021	Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17beta-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes.	hydroxytamoxifen	76-94	sulfotransferase family 1E member 1	Homo sapiens	16-23
33112838-4	2021	Therefore, we determined whether expression of SSP enzymes, PSAT1 or phosphoglycerate dehydrogenase (PHGDH), affects the response of ER+ BC to 4-hydroxytamoxifen (4-OHT) treatment.	hydroxytamoxifen	143-161	phosphoserine aminotransferase 1	Homo sapiens	60-65
33112838-4	2021	Therefore, we determined whether expression of SSP enzymes, PSAT1 or phosphoglycerate dehydrogenase (PHGDH), affects the response of ER+ BC to 4-hydroxytamoxifen (4-OHT) treatment.	hydroxytamoxifen	143-161	phosphoglycerate dehydrogenase	Homo sapiens	69-99
33112838-4	2021	Therefore, we determined whether expression of SSP enzymes, PSAT1 or phosphoglycerate dehydrogenase (PHGDH), affects the response of ER+ BC to 4-hydroxytamoxifen (4-OHT) treatment.	hydroxytamoxifen	143-161	phosphoglycerate dehydrogenase	Homo sapiens	101-106
33112838-4	2021	Therefore, we determined whether expression of SSP enzymes, PSAT1 or phosphoglycerate dehydrogenase (PHGDH), affects the response of ER+ BC to 4-hydroxytamoxifen (4-OHT) treatment.	hydroxytamoxifen	143-161	epiregulin	Homo sapiens	133-135
33064293-0	2021	Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17beta-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes.	hydroxytamoxifen	76-94	sulfotransferase family 1E member 1	Homo sapiens	122-129
33064293-1	2021	BACKGROUND AND OBJECTIVES: Previous studies have revealed that sulfation, as mediated by the estrogen-sulfating cytosolic sulfotransferase (SULT) SULT1E1, is involved in the metabolism of 17beta-estradiol (E2), 4-hydroxytamoxifen (4OH-tamoxifen), and diethylstilbestrol in humans.	hydroxytamoxifen	211-229	sulfotransferase family 1E member 1	Homo sapiens	146-153
33064293-1	2021	BACKGROUND AND OBJECTIVES: Previous studies have revealed that sulfation, as mediated by the estrogen-sulfating cytosolic sulfotransferase (SULT) SULT1E1, is involved in the metabolism of 17beta-estradiol (E2), 4-hydroxytamoxifen (4OH-tamoxifen), and diethylstilbestrol in humans.	hydroxytamoxifen	231-244	sulfotransferase family 1E member 1	Homo sapiens	146-153
33064293-3	2021	METHODS: In this study, five missense coding single nucleotide polymorphisms of the SULT1E1 gene were selected to investigate the sulfating activity of the coded SULT1E1 allozymes toward E2, 4OH-tamoxifen, and diethylstilbestrol.	hydroxytamoxifen	191-204	sulfotransferase family 1E member 1	Homo sapiens	84-91
33064293-3	2021	METHODS: In this study, five missense coding single nucleotide polymorphisms of the SULT1E1 gene were selected to investigate the sulfating activity of the coded SULT1E1 allozymes toward E2, 4OH-tamoxifen, and diethylstilbestrol.	hydroxytamoxifen	191-204	sulfotransferase family 1E member 1	Homo sapiens	162-169
33064293-5	2021	RESULTS: Purified SULT1E1 allozymes were shown to display differential sulfating activities toward E2, 4OH-tamoxifen, and diethylstilbestrol.	hydroxytamoxifen	103-116	sulfotransferase family 1E member 1	Homo sapiens	18-25
33064293-6	2021	Kinetic analysis revealed further distinct Km (reflecting substrate affinity) and Vmax (reflecting catalytic activity) values of the five SULT1E1 allozymes with E2, 4OH-tamoxifen, and diethylstilbestrol as substrates.	hydroxytamoxifen	165-178	sulfotransferase family 1E member 1	Homo sapiens	138-145
32619634-4	2020	All the tested bisphenol diglycidyl ethers fitted into the hydrophobic binding pocket and adopted the conformation that resembled 4-hydroxytamoxifen, a selective antagonist of ERalpha.	hydroxytamoxifen	130-148	estrogen receptor 1	Homo sapiens	176-183
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	202-220	estrogen receptor 1	Homo sapiens	70-87
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	202-220	estrogen receptor 1	Homo sapiens	89-91
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	202-220	estrogen receptor 2	Homo sapiens	6-9
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	202-220	estrogen receptor 1	Homo sapiens	150-152
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	222-225	estrogen receptor 1	Homo sapiens	70-87
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	222-225	estrogen receptor 1	Homo sapiens	89-91
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	222-225	estrogen receptor 2	Homo sapiens	6-9
33022466-8	2020	The v-Erb-B oncogene was ligated to the hormone binding domain of the estrogen receptor (ER) which results in regulation of the activity of the v-Erb-ER construct by addition of either estrogen (E2) or 4-hydroxytamoxifen (4HT) to the culture media.	hydroxytamoxifen	222-225	estrogen receptor 1	Homo sapiens	150-152
33064339-2	2020	The selective estrogen receptor modulators (SERMs), including 4-hydroxytamoxifen (4OHT), activate AF-1 preferentially rather than AF-2.	hydroxytamoxifen	62-80	proteasome (prosome, macropain) 26S subunit, non-ATPase, 4	Mus musculus	98-102
31785970-1	2020	Tamoxifen is a prodrug and cytochrome P450 2C9 (CYP2C9) has a significant role in the formation of a therapeutically more potent metabolite (4-hydroxytamoxifen) than tamoxifen.	hydroxytamoxifen	141-159	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	27-46
32043610-6	2020	Downregulating SOX11 expression can restore the sensitivity to 4-hydroxytamoxifen in MCF-7-Tam-R cells.	hydroxytamoxifen	63-81	SRY-box transcription factor 11	Homo sapiens	15-20
32724387-7	2020	AGR3 expression was upregulated in estrogen-treated T47D cells, whereas 4-hydroxytamoxifen, an inhibitor of estrogen-ER activity in breast cancer cells, downregulated AGR3 expression in T47D cells.	hydroxytamoxifen	72-90	estrogen receptor 1	Homo sapiens	117-119
32724387-7	2020	AGR3 expression was upregulated in estrogen-treated T47D cells, whereas 4-hydroxytamoxifen, an inhibitor of estrogen-ER activity in breast cancer cells, downregulated AGR3 expression in T47D cells.	hydroxytamoxifen	72-90	anterior gradient 3, protein disulphide isomerase family member	Homo sapiens	167-171
33013387-5	2020	Interestingly, we found that the level of PKM2 expression was upregulated in the tamoxifen resistant breast cancer cells MCF-7/TAMR, and knockdown of PKM2 sensitized the cells to 4-hydroxytamoxifen (4OH-T).	hydroxytamoxifen	179-197	pyruvate kinase M1/2	Homo sapiens	42-46
33013387-5	2020	Interestingly, we found that the level of PKM2 expression was upregulated in the tamoxifen resistant breast cancer cells MCF-7/TAMR, and knockdown of PKM2 sensitized the cells to 4-hydroxytamoxifen (4OH-T).	hydroxytamoxifen	179-197	pyruvate kinase M1/2	Homo sapiens	150-154
32302038-6	2020	Following co-injection of anti-hoxd4a MO with mRNA encoding the Hoxd4a-ERT2 fusion protein, hemangioblast specification was fully rescued when embryos were exposed to the estrogen analog 4-hydroxy-tamoxifen (4-OHT) at 4 hr post-fertilization (hpf), but only poorly at 6 hpf and not at all at 8 hpf, thereby defining a pre-gastrulation role for Hoxd4a, the earliest developmental function of a vertebrate Hox gene so far described.	hydroxytamoxifen	187-206	homeobox D4a	Danio rerio	31-37
32302038-6	2020	Following co-injection of anti-hoxd4a MO with mRNA encoding the Hoxd4a-ERT2 fusion protein, hemangioblast specification was fully rescued when embryos were exposed to the estrogen analog 4-hydroxy-tamoxifen (4-OHT) at 4 hr post-fertilization (hpf), but only poorly at 6 hpf and not at all at 8 hpf, thereby defining a pre-gastrulation role for Hoxd4a, the earliest developmental function of a vertebrate Hox gene so far described.	hydroxytamoxifen	187-206	homeobox D4a	Danio rerio	64-70
32302038-6	2020	Following co-injection of anti-hoxd4a MO with mRNA encoding the Hoxd4a-ERT2 fusion protein, hemangioblast specification was fully rescued when embryos were exposed to the estrogen analog 4-hydroxy-tamoxifen (4-OHT) at 4 hr post-fertilization (hpf), but only poorly at 6 hpf and not at all at 8 hpf, thereby defining a pre-gastrulation role for Hoxd4a, the earliest developmental function of a vertebrate Hox gene so far described.	hydroxytamoxifen	187-206	mitogen-activated protein kinase 3	Homo sapiens	71-75
31785970-1	2020	Tamoxifen is a prodrug and cytochrome P450 2C9 (CYP2C9) has a significant role in the formation of a therapeutically more potent metabolite (4-hydroxytamoxifen) than tamoxifen.	hydroxytamoxifen	141-159	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	48-54
31604073-5	2020	In cells with normal PTEN and ER beta status, after 6 days of treatment with 1 microM 4-OH tamoxifen, E2-driven proliferation was decreased by 64.5% in MCF-7 and by 57.7% in T-47D cells (both p<0.01).	hydroxytamoxifen	86-100	phosphatase and tensin homolog	Homo sapiens	21-25
32019136-4	2020	In our study, we constructed a homology-based 3D model of human AFP (HAFP) with the purpose of molecular docking of ERalpha ligands, three agonists (17beta-estradiol, estrone and diethylstilbestrol), and three antagonists (tamoxifen, afimoxifene and endoxifen) into the obtained structure.	hydroxytamoxifen	234-245	alpha fetoprotein	Homo sapiens	64-67
31604073-5	2020	In cells with normal PTEN and ER beta status, after 6 days of treatment with 1 microM 4-OH tamoxifen, E2-driven proliferation was decreased by 64.5% in MCF-7 and by 57.7% in T-47D cells (both p<0.01).	hydroxytamoxifen	86-100	estrogen receptor 2	Homo sapiens	30-37
31843009-9	2019	Upon activation of Cre activity with 4-hydroxytamoxifen (4-OHT) at any given time point, the recombinase excises a stop signal and poses the second component of the system-the FlpO recombinase, knocked into 3"UTR of Oct4, to be expressed upon activation of the latter gene.	hydroxytamoxifen	37-55	POU domain, class 5, transcription factor 1	Mus musculus	216-220
31195002-0	2019	Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.	hydroxytamoxifen	21-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
31807030-6	2019	Pharmacophore study showed that ChalcEA shares similar features with the known hERalpha antagonist, 4-hydroxytamoxifen (4-OHT), which has hydrogen bond donor (HBD), hydrogen bond acceptor (HBA), ring aromaticity (RA), and hydrophobicity (Hy) features.	hydroxytamoxifen	100-118	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	79-87
31195002-2	2019	Cytochrome P450 (CYP) 2D6 is crucial in the oxidation of tamoxifen to generate active metabolites, 4-hydroxytamoxifen and endoxifen.	hydroxytamoxifen	99-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-25
26169578-3	2015	A systematic analysis using 13 known human SULTs revealed SULT1A1 and SULT1C4 as the major SULTs responsible for the sulfation of afimoxifene, endoxifen, raloxifene and fulvestrant.	hydroxytamoxifen	130-141	sulfotransferase family 1A member 1	Homo sapiens	58-65
30937657-0	2019	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.	hydroxytamoxifen	0-18	estrogen receptor 1	Homo sapiens	43-66
30937657-0	2019	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.	hydroxytamoxifen	0-18	zinc finger protein 423	Homo sapiens	122-128
30760083-3	2019	Estrogen receptor positive MCF-7 cells were incubated with 4OH-tamoxifen (10 nM) and gene expression analyzed by array hybridization during 12 weeks.	hydroxytamoxifen	59-72	estrogen receptor 1	Homo sapiens	0-17
31455323-0	2019	Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells.	hydroxytamoxifen	91-110	C-type lectin domain containing 10A	Homo sapiens	62-69
31455323-5	2019	Estrogen- and stress dependent induction of CLEC10A ligands was analyzed in MCF7 and T47D cells exposed to 4-hydroxy-tamoxifen (Tam), zeocin and hydrogen peroxide.	hydroxytamoxifen	107-126	C-type lectin domain containing 10A	Homo sapiens	44-51
31455323-5	2019	Estrogen- and stress dependent induction of CLEC10A ligands was analyzed in MCF7 and T47D cells exposed to 4-hydroxy-tamoxifen (Tam), zeocin and hydrogen peroxide.	hydroxytamoxifen	128-131	C-type lectin domain containing 10A	Homo sapiens	44-51
31455323-9	2019	Accordingly, CLEC10A ligands were induced in MCF7- and T47D breast cancer cells after Tam treatment and accumulated on the cell surface and in the endosomal/lysosomal compartment.	hydroxytamoxifen	86-89	C-type lectin domain containing 10A	Homo sapiens	13-20
31455323-15	2019	CONCLUSION: CLEC10A ligands are inducible by hormone depletion, 4-hydroxy-tamoxifen and agents inducing DNA damage and oxidative stress.	hydroxytamoxifen	64-83	C-type lectin domain containing 10A	Homo sapiens	12-19
31670920-12	2019	With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	66-84	transforming growth factor alpha	Homo sapiens	5-9
31670920-12	2019	With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	66-84	epiregulin	Homo sapiens	24-26
33418733-7	2018	Interestingly, large microtumors also lost estrogen receptor alpha (ER-alpha) protein, consequently showing resistance to 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	122-140	estrogen receptor 1	Homo sapiens	68-76
29130361-4	2018	Here, we report that the level of MTA1 expression was upregulated in the tamoxifen resistant breast cancer cell lines MCF7/TAMR and T47D/TR, and knockdown of MTA1 sensitized the cells to 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	187-205	metastasis associated 1	Homo sapiens	34-38
29130361-4	2018	Here, we report that the level of MTA1 expression was upregulated in the tamoxifen resistant breast cancer cell lines MCF7/TAMR and T47D/TR, and knockdown of MTA1 sensitized the cells to 4-hydroxytamoxifen (4OHT).	hydroxytamoxifen	187-205	metastasis associated 1	Homo sapiens	158-162
26169578-3	2015	A systematic analysis using 13 known human SULTs revealed SULT1A1 and SULT1C4 as the major SULTs responsible for the sulfation of afimoxifene, endoxifen, raloxifene and fulvestrant.	hydroxytamoxifen	130-141	sulfotransferase family 1C member 4	Homo sapiens	70-77
23418355-7	2013	We further demonstrate that tamoxifen and its metabolite 4-hydroxytamoxifen lead to prion degradation in an autophagy-independent manner by diverting the trafficking of both PrP and cholesterol to lysosomes.	hydroxytamoxifen	57-75	prion protein	Mus musculus	174-177
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	vascular endothelial growth factor A	Mus musculus	212-221
34815764-6	2022	Furthermore, when H19 was knocked down in the MCF-7R cells, the sensitivity to 4-hydroxytamoxifen was markedly restored.	hydroxytamoxifen	79-97	H19 imprinted maternally expressed transcript	Homo sapiens	18-21
16182609-4	2006	Treatment with 4-hydroxytamoxifen, a synthetic estrogen receptor modulator, activated Cre recombinase within the transduced neurons and induced selective excision of the tyrosine hydroxylase (TH) coding sequence flanked by loxP sites, leading to a reduction in transgene-mediated dopamine synthesis.	hydroxytamoxifen	15-33	tyrosine hydroxylase	Rattus norvegicus	170-190
16182609-4	2006	Treatment with 4-hydroxytamoxifen, a synthetic estrogen receptor modulator, activated Cre recombinase within the transduced neurons and induced selective excision of the tyrosine hydroxylase (TH) coding sequence flanked by loxP sites, leading to a reduction in transgene-mediated dopamine synthesis.	hydroxytamoxifen	15-33	tyrosine hydroxylase	Rattus norvegicus	192-194
34890638-8	2022	Imatinib in combination with 4-hydroxytamoxifen showed concentration-dependent effects on the metabolic activity of ERalpha-expressing AN3CA, MCF-7, and SKOV3 cells, and on cell proliferation and adhesion of MCF-7 cells.	hydroxytamoxifen	29-47	estrogen receptor 1	Homo sapiens	116-123
34925236-4	2021	Methods: Dmp1-CreERt2:mTmG mice were injected with 0.5 mg of 4-hydroxytamoxifen once weekly from postnatal week 4 to week 8.	hydroxytamoxifen	61-79	dentin matrix protein 1	Mus musculus	9-13
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	estrogen receptor 1 (alpha)	Mus musculus	259-266
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	G protein-coupled receptor 1	Mus musculus	272-300
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	G protein-coupled receptor 1	Mus musculus	302-307
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	345-349
34653752-5	2021	We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGFalpha and other immune activation genes by ERalpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms.	hydroxytamoxifen	17-20	thymoma viral proto-oncogene 1	Mus musculus	363-366
34433666-5	2021	As functional analyses, we manipulated TRIM47 expression in estrogen receptor-positive breast cancer cells MCF-7 and its 4-hydroxytamoxifen (OHT)-resistant derivative OHTR, which was established in a long-term culture with OHT.	hydroxytamoxifen	121-139	tripartite motif containing 47	Homo sapiens	39-45
34419761-9	2021	Moreover, 4-hydroxytamoxifen (4-OHT), an estrogen receptor (ER) antagonist, blocked Rim"s and EB"s facilitating effect.	hydroxytamoxifen	10-28	estrogen receptor 1 (alpha)	Mus musculus	41-58
34419761-9	2021	Moreover, 4-hydroxytamoxifen (4-OHT), an estrogen receptor (ER) antagonist, blocked Rim"s and EB"s facilitating effect.	hydroxytamoxifen	10-28	estrogen receptor 1 (alpha)	Mus musculus	60-62
34572047-4	2021	In the therapy of estrogen receptor alpha (ERalpha)-positive breast cancer (BC), the focus lies on hormone sensitivity targeting therapy with selective estrogen receptor modulators (SERMs) such as 4-hydroxytamoxifen (4-OHT), although this therapy is partially limited by the development of resistance.	hydroxytamoxifen	197-215	estrogen receptor 1	Homo sapiens	18-41
34572047-4	2021	In the therapy of estrogen receptor alpha (ERalpha)-positive breast cancer (BC), the focus lies on hormone sensitivity targeting therapy with selective estrogen receptor modulators (SERMs) such as 4-hydroxytamoxifen (4-OHT), although this therapy is partially limited by the development of resistance.	hydroxytamoxifen	197-215	estrogen receptor 1	Homo sapiens	43-50
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	145-163	ribosomal protein S14	Homo sapiens	26-31
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	145-163	estrogen receptor 1	Homo sapiens	67-84
34261921-2	2021	Previously, we found that RPS14 was significantly downregulated in estrogen receptor-positive (ER+) breast cancer cells following treatment with 4-hydroxytamoxifen (4-OH-TAM).	hydroxytamoxifen	145-163	epiregulin	Homo sapiens	95-97
34433666-5	2021	As functional analyses, we manipulated TRIM47 expression in estrogen receptor-positive breast cancer cells MCF-7 and its 4-hydroxytamoxifen (OHT)-resistant derivative OHTR, which was established in a long-term culture with OHT.	hydroxytamoxifen	121-139	estrogen receptor 1	Homo sapiens	60-77
34213887-3	2021	In addition, ATF3 protein expression is positively correlated with the resistance of TamR MCF-7 cells to 4-hydroxytamoxifen (4-OHT).	hydroxytamoxifen	105-123	activating transcription factor 3	Homo sapiens	13-17
34502280-5	2021	17beta-estradiol (E2) and 4-hydroxytamoxifen (OHT) were docked in the ligand binding pockets of the agonist and antagonist bound ERalpha.	hydroxytamoxifen	26-44	estrogen receptor 1	Homo sapiens	129-136
34284709-3	2021	The CreERT2/loxP system allows obtaining an inducible knockout in cells expressing tamoxifen-inducible Cre recombinase (CreERT2) and containing loxP sites flanking the target gene by adding 4-hydroxy tamoxifen to the culture medium.	hydroxytamoxifen	190-209	mitogen activated protein kinase 3	Rattus norvegicus	4-11
34072800-1	2021	DN203368 ((E)-3-(1-(4-(4-isopropylpiperazine-1-yl)phenyl) 3-methyl-2-phenylbut-1-en-1-yl) phenol) is a 4-hydroxy tamoxifen analog that is a dual inverse agonist of estrogen-related receptor beta/gamma (ERRbeta/gamma).	hydroxytamoxifen	103-122	estrogen related receptor beta	Homo sapiens	164-200
34264479-12	2021	RUNX1T1 mRNA expression was analyzed by qRT-PCR in MCF-7 or T47D cells, which were treated with 17beta-estradiol, or the ERalpha agonist PPT, alone or in combination with 4-hydroxytamoxifen.	hydroxytamoxifen	171-189	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	0-7
34072800-1	2021	DN203368 ((E)-3-(1-(4-(4-isopropylpiperazine-1-yl)phenyl) 3-methyl-2-phenylbut-1-en-1-yl) phenol) is a 4-hydroxy tamoxifen analog that is a dual inverse agonist of estrogen-related receptor beta/gamma (ERRbeta/gamma).	hydroxytamoxifen	103-122	estrogen related receptor alpha	Homo sapiens	202-215
35588983-6	2022	This effect was partially reversed by siRNA-mediated silencing of ERalpha expression and by 4-hydroxytamoxifen (ERalpha antagonist), but neither by G36 (GPER antagonist) nor by the siRNA-mediated silencing of PPARgamma2 expression.	hydroxytamoxifen	92-110	estrogen receptor 1	Homo sapiens	112-119
34471053-0	2021	Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1alpha Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.	hydroxytamoxifen	43-61	solute carrier family 16 member 3	Homo sapiens	30-34
34471053-0	2021	Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1alpha Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.	hydroxytamoxifen	43-61	hypoxia inducible factor 1 subunit alpha	Homo sapiens	88-98
35581155-5	2022	Transgenic lines carrying a CAG promoter-driven Cre-ERT2 /loxP system showed conditional labeling of muscle, epidermal and interstitial cells both in the tadpole tail and the froglet leg upon 4-hydroxytamoxifen (4OHT) treatment.	hydroxytamoxifen	192-210	mitogen-activated protein kinase 3	Mus musculus	52-56
35582941-1	2022	BACKGROUND: The most-common strategy for zebrafish Cre/lox-mediated lineage labeling experiments combines ubiquitously expressed, lox-based Switch reporter transgenes with tissue-specific Cre or 4-OH-Tamoxifen-inducible CreERT2 driver lines.	hydroxytamoxifen	195-209	lysyl oxidase a	Danio rerio	55-58
35582941-1	2022	BACKGROUND: The most-common strategy for zebrafish Cre/lox-mediated lineage labeling experiments combines ubiquitously expressed, lox-based Switch reporter transgenes with tissue-specific Cre or 4-OH-Tamoxifen-inducible CreERT2 driver lines.	hydroxytamoxifen	195-209	lysyl oxidase a	Danio rerio	130-133
35168026-6	2022	Following an initial 60 min exposure to foster pups, virgin TRAP2;Ai14 mice were injected with 4-hydroxytamoxifen to induce recombination in c-Fos expressing cells and subsequent permanent expression of a red fluorescent reporter.	hydroxytamoxifen	95-113	FBJ osteosarcoma oncogene	Mus musculus	141-146
35476451-6	2022	Consequently, MYCi975 synergistically sensitized resistant prostate cancer cells to enzalutamide and estrogen receptor-positive breast cancer cells to 4-hydroxytamoxifen.	hydroxytamoxifen	151-169	estrogen receptor 1	Homo sapiens	101-118
35263700-0	2022	Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells.	hydroxytamoxifen	43-61	acyl-CoA synthetase short chain family member 1	Homo sapiens	23-28
35263700-0	2022	Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells.	hydroxytamoxifen	43-61	acyl-CoA synthetase short chain family member 2	Homo sapiens	33-38
35477414-2	2022	Competitive ERalpha blockers such as 4-Hydroxytamoxifen (OHT), are synthetic FDA approved drugs which, albeit being an effective anticancer agent, induces life altering side effects.	hydroxytamoxifen	37-55	estrogen receptor 1	Homo sapiens	12-19
35088889-9	2022	While 4-hydroxytamoxifen (4-OHT) increased ATG4A expression in MCF7 and MCF7/R cells, ATG4A expression decreased in the cells treated with 3-methyladenine (3MA).	hydroxytamoxifen	6-24	autophagy related 4A cysteine peptidase	Homo sapiens	43-48
35205702-10	2022	Treatment of SPRED2-deficient breast cancer cells with a combination of the ERK 1/2 inhibitor ulixertinib and 4-hydroxytamoxifen (4-OHT) can inhibit cell growth and proliferation and overcome the induced tamoxifen resistance.	hydroxytamoxifen	110-128	sprouty related EVH1 domain containing 2	Homo sapiens	13-19
35205702-10	2022	Treatment of SPRED2-deficient breast cancer cells with a combination of the ERK 1/2 inhibitor ulixertinib and 4-hydroxytamoxifen (4-OHT) can inhibit cell growth and proliferation and overcome the induced tamoxifen resistance.	hydroxytamoxifen	110-128	mitogen-activated protein kinase 3	Homo sapiens	76-83
35174936-8	2022	Consistently, TRIM39 knockdown significantly suppressed proliferation and cell cycle transition to S phase in MCF-7 and 4-hydroxytamoxifen-resistant (OHTR) breast cancer cells.	hydroxytamoxifen	120-138	tripartite motif containing 39	Homo sapiens	14-20
35140234-4	2022	EMT was induced in the HMLE and MCF10A cell lines and in the HMLE-Twist-ER and HMLE-Snail-ER cell lines by prolonged exposure to TGFbeta1 or 4-hydroxytamoxifen, respectively.	hydroxytamoxifen	141-159	twist family bHLH transcription factor 1	Homo sapiens	66-71